Keros Therapeutics price target lowered to $32 from $33 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares. The firm notes frustrations from bulls, with shares trading absent much value for the Takeda (TAK) deal, but whether cibotercept and KER-065 are meaningful drags on sentiment or the P&L, as argued by activist ADAR1 Capital Management, is “less clear to us,” the analyst tells investors.